Mutagenic potential of anti-herpes agents

• Published in: Life sciences (1973) Vol. 38; no. 3; p. 281
• Main Authors: De Clercq, E, Cassiman, J J
• Format: Journal Article
• Language: English
• Published: Netherlands 20.01.1986
• Subjects: Acyclovir - pharmacology; Antiviral Agents - pharmacology; Cytosine - analogs & derivatives; Cytosine - pharmacology; Guanine - analogs & derivatives; Guanine - pharmacology; Herpes Simplex - drug therapy; Humans; Lymphocytes - drug effects; Lymphocytes - ultrastructure; Mutagenicity Tests; Sister Chromatid Exchange - drug effects; Uridine - analogs & derivatives; Uridine - pharmacology
• ISSN: 0024-3205
• DOI: 10.1016/0024-3205(86)90314-0

A number of anti-herpes agents which are either licensed for clinical use (acyclovir) or subject of clinical studies (bromovinyldeoxyuridine, fluoroiodoaracytidine, dihydroxypropoxymethylguanine) or under preclinical investigation (i.e., fluoroiodoarauridine), fluoromethylarauridine, dihydroxybutylguanine, bromovinyldeoxycytidine, bromovinylarauridine and carbocyclic bromovinyldeoxyuridine) were evaluated for their ability to induce sister chromatid exchange (SCE), an indicator of mutagenesis. SCE was scored on metaphase chromosomes of human lymphocytes which had been exposed to 5-bromo-2'-deoxyuridine and varying concentrations of the test compounds. The antiviral assays were based on the inhibition of the cytopathogenicity of herpes simplex virus for human diploid fibroblasts. Most compounds, i.e. acyclovir, bromovinyldeoxyuridine or carbocyclic bromovinyldeoxyuridine, did either not induce SCE or only so at concentrations far above their minimum antiviral concentrations. However, fluoroiodoaracytidine and dihydroxypropoxymethylguanine were found to affect the SCE rate at a concentration (greater than or equal to 4.5 micrograms/ml) that is readily achievable in blood following intravenous injection.